These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9928548)

  • 1. Determination of clinical utility of tumor markers: a tumor marker utility grading system.
    Hayes DF
    Recent Results Cancer Res; 1998; 152():71-85. PubMed ID: 9928548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?
    Hayes DF; Trock B; Harris AL
    Breast Cancer Res Treat; 1998; 52(1-3):305-19. PubMed ID: 10066089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
    Hayes DF; Bast RC; Desch CE; Fritsche H; Kemeny NE; Jessup JM; Locker GY; Macdonald JS; Mennel RG; Norton L; Ravdin P; Taube S; Winn RJ
    J Natl Cancer Inst; 1996 Oct; 88(20):1456-66. PubMed ID: 8841020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues in clinical trial design for tumor marker studies.
    Sargent D; Allegra C
    Semin Oncol; 2002 Jun; 29(3):222-30. PubMed ID: 12063675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].
    Bellocq JP; Luporsi E; Barrière J; Bonastre J; Chetritt J; Le Corroller AG; de Crémoux P; Fina F; Gauchez AS; Kassab-Chahmi D; Lamy PJ; Martin PM; Mazouni C; Peyrat JP; Romieu G; Verdoni L; Mazeau-Woynar V
    Ann Pathol; 2014 Oct; 34(5):349-51. PubMed ID: 25439987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expert system approach for the objective interpretation of serum tumour marker levels.
    Stajić S; Novaković R; Bosnjaković V
    Nucl Med Commun; 1994 Apr; 15(4):298-304. PubMed ID: 8072745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum (circulating) tumor markers for breast cancer.
    Hayes DF
    Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of
    Han N; Sun X; Qin C; Hassan Bakari K; Wu Z; Zhang Y; Lan X
    AJR Am J Roentgenol; 2018 May; 210(5):1155-1163. PubMed ID: 29629798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor marker utility grading system.
    Prentice RL
    J Natl Cancer Inst; 1996 Oct; 88(20):1419-20. PubMed ID: 8841012
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
    Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
    Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
    Stearns V; Yamauchi H; Hayes DF
    Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomolecular markers of breast cancer.
    Nicolini A; Carpi A; Tarro G
    Front Biosci; 2006 May; 11():1818-43. PubMed ID: 16368559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminally expressed gastrointestinal biomarkers.
    Cummins G; Yung DE; Cox BF; Koulaouzidis A; Desmulliez MPY; Cochran S
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1119-1134. PubMed ID: 28849686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New diagnostic markers for malignant pleural mesothelioma].
    Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
    Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.
    Draht MXG; Goudkade D; Koch A; Grabsch HI; Weijenberg MP; van Engeland M; Melotte V; Smits KM
    Clin Epigenetics; 2018; 10():35. PubMed ID: 29564023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
    Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
    Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Judging new markers by their ability to improve predictive accuracy.
    Kattan MW
    J Natl Cancer Inst; 2003 May; 95(9):634-5. PubMed ID: 12734304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.